AMENDMENTS TO THE CLAIMS

This Listing of the Claims will replace all prior versions and listings of claims in the application:

Listing of Claims

1. (Currently Amended) A compound of the formula:



(A)

wherein:

X is —O, —CH_2, —CH(C_{1-4} alkyl), —CH(C_{3-6} cycloalkyl), —S, [[—]]arylene, or [[—]]arylalkylene;

R is —H, [[—]]C_{1-4} alkyl optionally containing one or more heteroatoms selected from O, S, or N in the chain, [[—]]C_{3-6} cycloalkyl optionally containing one or more heteroatoms selected from O, S, or N in the ring, [[—]]aryl, arylalkyl, or heterocycle;

Y is —H, [[—]]C_{1-4} alkyl, or [[—]]C_{3-6} cycloalkyl;

Z is [[—]]C_{1-4} alkyl[[,]] or [[—]]C_{3-6} cycloalkyl;

R_1, R_2, R_3, R_4, and R_5 are each independently [[is]] —H, [[—]]C_{1-4} alkyl, halogen, —NO_2, —OW ~~(wherein W is —H, —CH_3, aryl)~~, or —SW, [[()]]wherein W is —H, —CH_3, or [[—]]aryl[[()]];

~~R_2 is —H, —C_{1-4} alkyl, halogen, —NO_2, —OW (wherein W is —H, —CH_3, aryl), —SW (wherein W is —H, —CH_3, aryl);~~

~~R_3 is —H, —C_{1-4} alkyl, halogen, —NO_2, —OW (wherein W is —H, —CH_3, aryl), —SW (wherein W is —H, —CH_3, aryl);~~

~~R_4 is —H, —C_{1-4} alkyl, halogen, —NO_2, —OW (wherein W is —H, —CH_3, aryl), —SW (wherein W is —H, —CH_3, aryl);~~

~~R_5 is —H, —C_{1-4} alkyl, halogen, —NO_2, —OW (wherein W is —H, —CH_3, aryl), —SW (wherein W is —H, —CH_3, aryl);~~ and

R_1 and R_2 are optionally CH=CH-CH=CH;

or a pharmaceutically acceptable salt thereof.

2. (Canceled).

3. (Currently Amended) [[A]] The compound of ~~having formula A as claimed in~~ claim 1, wherein

X = S	Y = H	Z = CH_3	R = *i*Pr	R_1 = Cl	R_2 = H	R_3 = H	R_4 = H	R_5 = Cl;
X = S	Y = H	Z = CH_3	R = Pen	R_1 = Cl	R_2 = H	R_3 = H	R_4 = H	R_5 = Cl;
X = S	Y = H	Z = Et	R = *i*Bu	R_1 = Cl	R_2 = H	R_3 = H	R_4 = H	R_5 = Cl;
X = S	Y = H	Z = Et	R = *i*Pen	R_1 = Cl	R_2 = H	R_3 = H	R_4 = H	R_5 = Cl;
X = S	Y = H	Z = CH_3	R = *i*Pr	R_1 = F	R_2 = H	R_3 = H	R_4 = H	R_5 = F;
X = S	Y = H	Z = CH_3	R = *i*Bu	R_1 = F	R_2 = H	R_3 = H	R_4 = H	R_5 = F;
X = S	Y = H	Z = CH_3	R = *n*Bu	R_1 = F	R_2 = H	R_3 = H	R_4 = H	R_5 = F;
X = S	Y = H	Z = CH_3	R = *s*Bu	R_1 = F	R_2 = H	R_3 = H	R_4 = H	R_5 = F;
X = S	Y = H	Z = CH_3	R = *c*Pen	R_1 = F	R_2 = H	R_3 = H	R_4 = H	R_5 = F;
X = S	Y = H	Z = CH_3	R = *c*Es	R_1 = F	R_2 = H	R_3 = H	R_4 = H	R_5 = F;
X = S	Y = H	Z = Et	R = *i*Pr	R_1 = F	R_2 = H	R_3 = H	R_4 = H	R_5 = F;
X = S	Y = H	Z = Et	R = *c*Pen	R_1 = F	R_2 = H	R_3 = H	R_4 = H	R_5 = F;
X = S	Y = CH_3	Z = CH_3	R = CH_3	R_1 = F	R_2 = H	R_3 = H	R_4 = H	R_5 = F;
X = S	Y = CH_3	Z = CH_3	R = CH_3	R_1 = F	R_2 = H	R_3 = H	R_4 = H	R_5 = F;
X = S	Y = CH_3	Z = CH_3	R = *s*Bu	R_1 = F	R_2 = H	R_3 = H	R_4 = H	R_5 = F;
X = S	Y = CH_3	Z = CH_3	R = *c*Pe	R_1 = F	R_2 = H	R_3 = H	R_4 = H	R_5 = F;
X = S	Y = CH_3	Z = CH_3	R = *i*Pr	R_1 = F	R_2 = H	R_3 = H	R_4 = H	R_5 = F;
X = S	Y = CH_3	Z = CH_3	R = *n*Bu	R_1 = F	R_2 = H	R_3 = H	R_4 = H	R_5 = F; or
X = S	Y = CH_3	Z = CH_3	R = *i*Bu	R_1 = F	R_2 = H	R_3 = H	R_4 = H	R_5 = F.

4. (Canceled).

5. (Currently Amended) A pharmaceutically acceptable salt of [[a]] the compound of claim 1.

6. (Currently Amended) A process for the preparation of a compound of ~~having formula A as claimed in~~ claim 1, wherein X = O, comprising the steps of reacting a ~~wherein the proper~~ methyl arylacetylalkylacetate ~~is reacted~~ with O-methylisourea in presence of calcium hydroxide to generate a 2-O-methyl(5-alkyl)-6-benzyl(substituted)uracil; and reacting the 2-O-methyl(5-alkyl)-6-benzyl(substituted)uracil ~~the so obtained 2-O-methyl(5-~~

~~alkyl) 6-benzyl(substituted)uracils are reacted~~ with a ~~the proper~~ potassium alkoxide ~~according to scheme A~~.

7. (Currently Amended) A process for the preparation of a compound of ~~having formula A as claimed in~~ claim 1, wherein X = S, comprising the steps of reacting a ~~wherein the proper~~ methyl arylacetylalkylacetate ~~is reacted~~ with O-methylisourea in presence of calcium hydroxide to generate a 2-O-methyl(5-alkyl)-6-benzyl(substituted)uracil; and reacting the 2-O-methyl(5-alkyl)-6-benzyl(substituted)uracil ~~the so obtained 2-O-methyl(5-alkyl) 6-benzyl(substituted)uracils are reacted~~ with a ~~the proper~~ potassium alkoxide ~~according to scheme B~~.

8. (Canceled).

9. (Currently Amended) A method of treating infection by HIV or ~~of treating~~ AIDS, comprising administering to a mammal an effective amount of a compound of ~~as claimed in~~ claim 1 or a pharmaceutically acceptable salt thereof.

10. (Canceled).

11. (Currently Amended) A pharmaceutical composition comprising a compound of ~~as claimed in~~ claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

12. (Currently Amended) A method of treating infection by HIV or ~~of treating~~ AIDS, comprising administering to a mammal an effective amount of a compound of ~~as claimed in~~ claim 1 or a pharmaceutically acceptable salt thereof, in combination with another anti-HIV agent selected from the group consisting of abacavir, zidovudine, BILA 1906, BILA 2185, BM+51.0836~~: triazoloisoindolinone derivative~~, BMS 186,318~~: aminodiol derivative HIV-1 protease inhibitor~~, d4API, stavudine, efavirenz, HBY097, HEPT, KNI-272, L697,593, L-735,524, L-697,661, L-FDDC, L-FDOC, nevirapine, foscarnet, PMEA, PMPA, Ro 31-8959, RPI-3121, SC-52151, SC-55389A, TIBO R82150, TIBO 82913, TSAO-m3T, U90152, UC[[:]] thiocarboxanilide derivatives[[,]] such as UC-781[[,]] and UC-82, VB 11,328, amprenavir, XM 323, delaviridine, famciclovir, gancyclovir, penciclovir, indinavir, nelfinavir, ritonavir, saquinavir, DDI, DDC, [[D]]delaviridine, β-LddA, β-L-3'-azido-d5FC, carbovir, acyclovir, interferon, stavudine, [[(]]3'-azido-2',3'-dideoxy-5-methyl-cytidine[[)]],

3'-azido nucleosides, β-D-dioxolane nucleosides such as β-D-dioxolanylguanine (DXG), β-D-dioxolanyl-2,6-diaminopurine (DAPD), and β-D-dioxolanyl-6-chloropurine (ACP), D4T, FTC, 3TC, AZDU, and amprenavir.

13. (Currently Amended) A compound of the formula:



(B)

wherein:

X is —O, —CH_2, —CH(C_{1-4} alkyl), —CH(C_{3-6} cycloalkyl), —S, [[-]]arylene, or [[-]]arylalkylene;

R is —H, [[-]]C_{1-4} alkyl optionally containing one or more heteroatoms selected from O, S or N in the chain, [[-]]C_{3-6} cycloalkyl optionally containing one or more heteroatoms selected from O, S or N in the ring, [[-]]aryl, arylalkyl, or heterocycle

Y is —H, [[-]]C_{1-4} alkyl, or [[-]]C_{3-6} cycloalkyl;

Z is —H, [[—]]C_{1-4} alkyl, or [[-]]C_{3-6} cycloalkyl;

R_1 is [[–]]C_{1-4} alkyl, halogen, —NO_2, —OW ~~(wherein W is –H, –CH_3, –aryl)~~, or —SW_2 [[(]]wherein W is —H, —CH_3, or [[–]]aryl[[)]];

R_2, R_3, R_4, and R_5 are each independently [[is]] —H, [[—]]C_{1-4} alkyl, halogen, —NO_2, —OW ~~(wherein W is –H, –CH_3, –aryl)~~, or —SW_2 [[(]]wherein W is —H, —CH_3, or [[—]]aryl[[)]];

~~R_3 is –H, –C_{1-4} alkyl, halogen, –NO_2, –OW (wherein W is –H, –CH_3, –aryl), –SW (wherein W is –H, –CH_3, –aryl);~~

~~R_4 is –H, –C_{1-4} alkyl, halogen, –NO_2, –OW (wherein W is –H, –CH_3, –aryl), –SW (wherein W is –H, –CH_3, –aryl);~~

~~R_5 is –H, –C_{1-4} alkyl, halogen, –NO_2, –OW (wherein W is –H, –CH_3, –aryl), –SW (wherein W is –H, –CH_3, –aryl);~~ and

R_1 and R_2 are optionally CH=CH-CH=CH;

or a pharmaceutically acceptable salt thereof.

14. (Currently Amended) A compound of ~~having formula B as claimed in~~ claim 13, wherein

X = O Y = H Z = H R = *s*Bu R_1 = F R_2 = H R_3 = H R_4= H R_5 = F; or

X = O Y = H Z = H R = *c*Pen R_1 = F R_2 = H R_3 = H R_4= H R_5 = F.

15. (Currently Amended) A compound of ~~having formula B as claimed in~~ claim 13, wherein

X = S	Y = H	Z = H	R = *s*Bu	R_1 = NO_2	R_2 = H	R_3 = H	R_4 = H	R_5 = H;
X = S	Y = H	Z = H	R = *s*Bu	R_1 = F	R_2 = H	R_3 = H	R_4 = H	R_5 = H;
X = S	Y = H	Z = H	R = CH_3	R_1 = Cl	R_2 = H	R_3 = H	R_4 = H	R_5 = Cl;
X = S	Y = H	Z = H	R = iPr	R_1 = Cl	R_2 = H	R_3 = H	R_4 = H	R_5 = Cl;
X = S	Y = H	Z = H	R = *n*Bu	R_1 = Cl	R_2 = H	R_3 = H	R_4 = H	R_5 = Cl;
X = S	Y = H	Z = H	R = *i*Bu	R_1 = Cl	R_2 = H	R_3 = H	R_4 = H	R_5 = Cl;
X = S	Y = H	Z = H	R = *s*Bu	R_1 = Cl	R_2 = H	R_3 = H	R_4 = H	R_5 = Cl;
X = S	Y = H	Z = H	R = *c*Pen	R_1 = Cl	R_2 = H	R_3 = H	R_4 = H	R_5 = Cl;
X = S	Y = H	Z = H	R = CH_3	R_1 = F	R_2 = H	R_3 = H	R_4 = H	R_5 = F;
X = S	Y = H	Z = H	R = *i*Pr	R_1 = F	R_2 = H	R_3 = H	R_4 = H	R_5 = F;
X = S	Y = H	Z = H	R = *n*Bu	R_1 = F	R_2 = H	R_3 = H	R_4 = H	R_5 = F;
X = S	Y = H	Z = H	R = *i*Bu	R_1 = F	R_2 = H	R_3 = H	R_4 = H	R_5 = F;
X = S	Y = H	Z = H	R = *s*Bu	R_1 = F	R_2 = H	R_3 = H	R_4 = H	R_5 = F;
X = S	Y = H	Z = H	R = *c*Pen	R_1 = F	R_2 = H	R_3 = H	R_4 = H	R_5 = F;
X = S	Y = CH_3	Z = H	R = *s*Bu	R_1 = Cl	R_2 = H	R_3 = H	R_4 = H	R_5 = H;
X = S	Y = CH_3	Z = H	R = *s*Bu	R_1 = F	R_2 = H	R_3 = H	R_4 = H	R_5 = H;
X = S	Y = CH_3	Z = H	R = *s*Bu	R_1 = Cl	R_2 = H	R_3 = H	R_4 = H	R_5 = Cl;
X = S	Y = CH_3	Z = H	R = CH_3	R_1 = F	R_2 = H	R_3 = H	R_4 = H	R_5 = F;
X = S	Y = CH_3	Z = H	R = *i*Pr	R_1 = F	R_2 = H	R_3 = H	R_4 = H	R_5 = F;
X = S	Y = CH_3	Z = H	R = *n*Bu	R_1 = F	R_2 = H	R_3 = H	R_4 = H	R_5 = F;
X = S	Y = CH_3	Z = H	R = *i*Bu	R_1 = F	R_2 = H	R_3 = H	R_4 = H	R_5 = F;
X = S	Y = CH_3	Z = H	R = *s*Bu	R_1 = F	R_2 = H	R_3 = H	R_4 = H	R_5 = F;
X = S	Y = CH_3	Z = H	R = *c*Pen	R_1 = F	R_2 = H	R_3 = H	R_4 = H	R_5 = F;
X = S	Y = *i*Pr	Z = H	R = *i*Pr	R_1 = F	R_2 = H	R_3 = H	R_4 = H	R_5 = F;
X = S	Y = H	Z = H	R = MeSMe	R_1 = [[R]]F	R_2 = H	R_3 = H	R_4 = H	R_5 = F;
X = S	Y = CH_3	Z = H	R = MeSMe	R_1 = [[R]]F	R_2 = H	R_3 = H	R_4 = H	R_5 = F;
X = S	Y = Et	Z = H	R = MeSMe	R_1 = [[R]]F	R_2 = H	R_3 = H	R_4 = H	R_5 = F; or
X = S	Y = *i*Pr	Z = H	R = MeSMe	R_1 = [[R]]F	R_2 = H	R_3 = H	R_4 = H	R_5 = F.

16. (Previously Presented) A pharmaceutically acceptable salt of a compound of claim 13.

17. (Currently Amended) A process for the preparation of a compound of ~~having formula B as claimed in~~ claim 13, wherein X = O, comprising the steps of reacting a ~~wherein the proper~~ methyl arylacetylalkylacetate ~~is reacted~~ with O-methylisourea in presence of calcium hydroxide to generate a 2-O-methyl(5-alkyl)-6-benzyl(substituted)uracil; and reacting the so obtained 2-O-methyl(5-alkyl)-6-benzyl(substituted)uracil[[s]] ~~are reacted~~ with a ~~the proper~~ potassium alkoxide ~~according to scheme A~~.

18. (Currently Amended) A process for the preparation of a compound of ~~having formula B as claimed in~~ claim 13, wherein X = S, comprising the steps of reacting a ~~wherein the proper~~ methyl arylacetylalkylacetate ~~is reacted~~ with O-methylisourea in presence of calcium hydroxide to generate a 2-O-methyl(5-alkyl)-6-benzyl(substituted)uracil; and reacting the so obtained 2-O-methyl(5-alkyl)-6-benzyl(substituted)uracil[[s]] ~~are reacted~~ with a ~~the proper~~ potassium alkoxide ~~according to scheme B~~.

19. (Currently Amended) A method of treating infection by HIV[[,]] or ~~of treating~~ AIDS, comprising administering to a mammal an effective amount of a compound of ~~as claimed in~~ claim 13 or a pharmaceutically acceptable salt thereof.

20. (Currently Amended) A pharmaceutical composition comprising a compound of ~~as claimed in~~ claim 13 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

21. (Currently Amended) A method of treating infection by HIV or ~~of treating~~ AIDS, comprising administering to a mammal an effective amount of a compound of ~~as claimed in~~ claim 13 or a pharmaceutically acceptable salt thereof, in combination with another anti-HIV agent selected from the group consisting of abacavir, zidovudine, BILA 1906, BILA 2185, BM+51.0836~~: triazoloisoindolinone derivative~~, BMS 186,318~~: aminodiol derivative HIV-1 protease inhibitor~~, d4API, stavudine, efavirenz, HBY097, HEPT, KNI-272, L697,593, L-735,524, L-697,661, L-FDDC, L-FDOC, nevirapine, foscarnet, PMEA, PMPA, Ro 31-8959, RPI-3121, SC-52151, SC-55389A, TIBO R82150, TIBO 82913, TSAO-m3T, U90152, UC[[:]] thiocarboxanilide derivatives[[,]] such as UC-781[[,]] or UC-82, VB 11,328, amprenavir, XM 323, delaviridine, famciclovir, gancyclovir, penciclovir, indinavir,

nelfinavir, ritonavir, saquinavir, DDI, DDC, Delaviridine, β-LddA, β-L-3'-azido-d5FC, carbovir, acyclovir, interferon, stavudine, [[(]]3'-azido-2',3'-dideoxy-5-methyl-cytidine[[)]], 3'-azido nucleosides, β-D-dioxolane nucleosides such as β-D-dioxolanylguanine (DXG), β-D-dioxolanyl-2,6-diaminopurine (DAPD), and β-D-dioxolanyl-6-chloropurine (ACP), D4T, FTC, 3TC, AZDU, and amprenavir.

22. (New) The compound of claim 1, wherein R_1 is halo.

23. (New) The compound of claim 1, wherein R_5 is halo.

24. (New) The compound of claim 1, wherein R_1 and R_5 are independently halo.

25. (New) The compound of claim 1, wherein R_1 and R_5 are independently fluoro or chloro.

26. (New) The compound of claim 13, wherein R_1 is halo.

27. (New) The compound of claim 13, wherein R_5 is halo.

28. (New) The compound of claim 13, wherein R_1 and R_5 are independently halo.

29. (New) The compound of claim 13, wherein R_1 and R_5 are independently fluoro or chloro.